-- Mr. Cumbo, biotech industry veteran, brings commercial expertise
and strategic leadership in industry-leading commercial product launches
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 15, 2018--
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the election of
Bo Cumbo to its board of directors. Mr. Cumbo is a veteran of the
biotechnology industry and has played strategically important roles in
the successful launch of 11 products across multiple organizations and
therapeutic categories, including rare neuromuscular diseases,
hepatitis, HIV, and cardiovascular disease.
“In his more than twenty-year career in the biotechnology and
pharmaceutical sectors, Bo has played an integral role in the planning
and implementation of numerous, highly successful and industry-leading
commercial product launches,” said Doug Treco, PhD, President and Chief
Executive Officer of Ra Pharma. “With this deep expertise and global
commercial leadership experience, we are thrilled to welcome Bo to our
board and welcome the valuable insights he will bring.”
Mr. Cumbo serves as Senior Vice President and Chief Commercial Officer
of Cambridge, Massachusetts-based Sarepta Therapeutics, Inc.
(Nasdaq:SRPT), a leader in precision genetic medicine for rare diseases.
Mr. Cumbo joined Sarepta in 2013, leading and establishing the Company’s
commercial function as Sarepta developed into a global commercial
organization. During his tenure with Sarepta, Mr. Cumbo has been
responsible for directing one of the most successful ultra-rare product
launches in history for EXONDYS 51™ (eteplirsen). From 2010 to 2013, Mr.
Cumbo served as Vice President of Sales and Treatment Education for
Vertex Pharmaceuticals, launching Incivek, a treatment for hepatitis C.
Prior to Vertex, Mr. Cumbo served in multiple commercial roles
supporting the HIV, HBV, and cardiovascular franchises at Gilead
Sciences. Mr. Cumbo has extensive experience building pre- and
post-global commercial infrastructure, and throughout his career, he has
contributed to the launch of 11 specialty products across multiple
organizations. Mr. Cumbo received his Bachelor of Science in Medical
Technology from Auburn University.
“Ra Pharma has the potential to transform treatment paradigms across
multiple complement-mediated disorders,” said Mr. Cumbo. “This potential
begins with zilucoplan, a subcutaneously self-administered complement
inhibitor that, if approved, could disrupt standards of care by
affording patients greater accessibility, flexibility, and convenience.
I look forward to working with this dynamic and talented team at this
critical juncture in the Company’s life cycle.”
About Ra Pharmaceuticals
Ra Pharmaceuticals is a clinical stage biopharmaceutical company
focusing on the development of next-generation therapeutics for
complement-mediated diseases. The Company discovers and develops
peptides and small molecules to target key components of the complement
cascade. For more information, please visit: www.rapharma.com.
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding our potential to
transform treatment paradigms across multiple complement-mediated
disorders, the potential safety, efficacy and regulatory and clinical
progress of our product candidates, including without limitation
zilucoplan, and beliefs regarding clinical trial data. All such
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include the risks that Ra
Pharma's product candidates, including zilucoplan, will not successfully
be developed or commercialized, in the timeframe we expect or at all;
the risk that topline results as of February 7, 2017 from the Company's
global Phase 2 clinical program evaluating zilucoplan for the treatment
of PNH may not be indicative of final study results; the risk that USAN
does not approve the name zilucoplan; as well as the other factors
discussed in the "Risk Factors" section in Ra Pharma's most recently
filed Annual Report on Form 10-K, as well as other risks detailed in Ra
Pharma's subsequent filings with the Securities and Exchange Commission.
There can be no assurance that the actual results or developments
anticipated by Ra Pharma will be realized or, even if substantially
realized, that they will have the expected consequences to, or effects
on, Ra Pharma. All information in this press release is as of the date
of the release, and Ra Pharma undertakes no duty to update this
information unless required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181115005258/en/
Source: Ra Pharmaceuticals, Inc.
Natalie Wildenradt, 212-600-1902
David Rosen, 212-600-1902